Table of Contents
Volume 3 | Issue 2
Publication Date: September 2004- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
71-72 |
Prostate Cancer and Bone: A Unique Relationship with Multiple Opportunities for Targeted Therapy Oliver Sartor |
|
Meeting Highlights | ||
73-76 |
Highlights from: the 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA; June 2004 David Lee, Nancy Price, G. Kesava Reddy, Oliver Sartor, Vinay K. Jain |
|
Researches in Brief | ||
77-79 |
Benefit of Extended Zoledronate Therapy for Patients with Bone Metastases from Hormone-Refractory Prostate Cancer Nancy Price, Oliver Sartor, Vinay K. Jain |
|
80-82 |
Activity of Epothilone B Analogues Ixabepilone and Patupilone in Hormone-Refractory Prostate Cancer David Lee, Oliver Sartor, Vinay K. Jain |
|
Comprehensive Reviews | ||
83-86 |
Double Primary Cancers of the Prostate and Bladder: A Literature Review Yoshihisa Kinoshita, Amar Singh, Peter M. Rovito, Jr, Ching Y. Wang, Gabriel P. Haas |
|
87-92 |
Current Concepts in the Management of Erectile Dysfunction in Men with Prostate Cancer Muammer Kendirci, Wayne J.G. Hellstrom |
|
Original Contribution | ||
93-97 |
Effect of Pelvic Lymph Node Irradiation in Salvage Therapy for Patients with Prostate Cancer with a Biochemical Relapse Following Radical Prostatectomy Brian S. Kim, Ashkan Lashkari, Roy Vongtama, Steve P. Lee, Robert G. Parker |
|
Comprehensive Review | ||
98-103 |
Absence of a Correlation of Androgen Receptor Gene CAG Repeat Length and Prostate Cancer Risk in an African-American Population Timothy Gilligan, Judith Manola, Oliver Sartor, Sally P. Weinrich, Judd W. Moul, Philip W. Kantoff |
|
Original Contribution | ||
104-111 |
Phase II Randomized Trial of Weekly Paclitaxel with or Without Estramustine Phosphate in Progressive, Metastatic, Hormone-Refractory Prostate Cancer William R. Berry, James W. Hathorn, Shaker R. Dakhil, David M. Loesch, Don V. Jackson, Mary Ann Gregurich, Jennifer K. Newcomb-Fernandez, Lina Asmar |
|
Translational Medicine | ||
112-121 |
Anti-CD3 × Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancer-Bearing Severe Combined Immunodeficient Beige Mice Pamela A. Davol, Janelle A. Smith, Nicola Kouttab, Gerald J. Elfenbein, Lawrence G. Lum |
|
Brief Communication | ||
122-124 |
Second-Line Chemotherapy for Hormone-Refractory Prostate Cancer: Has the Time Come? Jonathan E. Rosenberg, Eric J. Small |
|